HDAC expression and clinical prognosis in human malignancies

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Histone deacetylases (HDACs) regulate cellular functions critical to cancer development and progression.
• HDAC inhibitors are actively investigated as anticancer agents for various malignancies.
• Research is increasingly focusing on the expression patterns of specific HDAC isoforms in tumors.

Purpose of the Study:

• To review and synthesize current findings on the expression patterns of HDAC isoforms in human tumors.
• To explore the correlation between HDAC isoform expression and clinicopathological features, including patient prognosis.
• To evaluate the potential of HDAC expression patterns as predictive biomarkers for response to HDAC inhibitor therapy.

Main Methods:

• Systematic review of studies investigating HDAC isoform expression (mRNA and protein levels) in various human neoplasms.
• Comparative analysis of HDAC expression in tumor tissues versus normal tissues of origin.
• Correlation analysis of HDAC expression with tumor grade, proliferation, stage, and patient survival data.

Main Results:

• Enhanced expression of Class I HDAC isoforms (mRNA and protein) is frequently observed in solid human tumors compared to normal tissues.
• Elevated Class I HDAC expression is often associated with advanced, dedifferentiated, and highly proliferative tumors.
• While sometimes linked to poorer prognosis, elevated Class I HDAC expression has also predicted better outcomes in specific cancer types.
• Conversely, Class II HDAC expression is often reduced in tumors, with high expression correlating with better patient outcomes in certain entities.

Conclusions:

• Differential expression of HDAC isoforms (Class I vs. Class II) is a common feature in human cancers.
• HDAC expression patterns show potential as prognostic indicators and may predict patient response to HDAC inhibitor therapies.
• Further translational studies are warranted to validate HDAC expression as a predictive biomarker for HDAC inhibitor treatment efficacy.